New to the par­ty, No­var­tis seeks to plunge in­to mR­NA

No­var­tis has been watch­ing the mR­NA par­ty from the out­side, and now, the Swiss drug­mak­er wants in.

Chair­man Jo­erg Rein­hardt told the Swiss Ger­man-lan­guage news­pa­per Aar­gauer Zeitung that the com­pa­ny is ready­ing an en­trance in­to the space that has dom­i­nat­ed head­lines late­ly, and be­come a house­hold name thanks to the suc­cess of Covid-19 vac­cines from Mod­er­na and Pfiz­er/BioN­Tech.

“The mR­NA tech­nol­o­gy has proven to be an at­trac­tive op­tion in this sit­u­a­tion and of course every re­search com­pa­ny is ques­tion­ing whether they should in­vest more in this area,” Rein­hardt told the pa­per. He al­so said mR­NA will be up for dis­cus­sion at its ex­ec­u­tive com­mit­tee meet­ing this week, and then in Au­gust with its board of di­rec­tors, ac­cord­ing to Reuters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER